International Journal of Endocrinology and Metabolism

Published by: Kowsar

Comparison of Osteoporosis Pharmacotherapy Fracture Rates: Analysis of a MarketScan® Claims Database Cohort

Alan W Reynolds 1 , Guodong Liu 2 , Paul T Kocis 3 , Jenna N Skowronski 4 , Douglas L Leslie 2 and Edward J Fox 1 , *
Authors Information
1 Orthopaedics and Rehabilitation, Pennsylvania State College of Medicine, Hershey, U.S.A.
2 Public Health Sciences, Pennsylvania State University, Hershey, U.S.A.
3 Pharmacy Disease Management, Pennsylvania State Hershey Medical Center, Hershey, U.S.A.
4 Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, U.S.A.
Article information
  • International Journal of Endocrinology and Metabolism: , In Press (In Press); e12104
  • Published Online: June 12, 2018
  • Article Type: Research Article
  • Received: April 25, 2017
  • Revised: April 10, 2018
  • Accepted: April 11, 2018
  • DOI: 10.5812/ijem.12104

To Cite: Reynolds A W, Liu G, Kocis P T, Skowronski J N, Leslie D L, et al. Comparison of Osteoporosis Pharmacotherapy Fracture Rates: Analysis of a MarketScan® Claims Database Cohort, Int J Endocrinol Metab. Online ahead of Print ;In Press(In Press):e12104. doi: 10.5812/ijem.12104.

Abstract
Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. [PubMed: 25182228]. [PubMed Central: PMC4176573].
  • 2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-75. doi: 10.1359/jbmr.061113. [PubMed: 17144789].
  • 3. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197-213. [PubMed: 18087050].
  • 4. Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1871-80. doi: 10.1210/jc.2011-3060. [PubMed: 22466336].
  • 5. Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord. 2011;12:209. doi: 10.1186/1471-2474-12-209. [PubMed: 21943363]. [PubMed Central: PMC3196921].
  • 6. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Silvestri S, et al. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int. 2008;19(8):1219-23. doi: 10.1007/s00198-008-0566-6. [PubMed: 18286217].
  • 7. Prieto-Alhambra D, Pages-Castella A, Wallace G, Javaid MK, Judge A, Nogues X, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268-74. doi: 10.1002/jbmr.2011. [PubMed: 23761350]. [PubMed Central: PMC3867340].
  • 8. Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int. 2014;25(4):1401-10. doi: 10.1007/s00198-014-2619-3. [PubMed: 24510095].
  • 9. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223-31. doi: 10.1007/s00198-011-1535-z. [PubMed: 21308365].
  • 10. Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PC, et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013;24(2):511-21. doi: 10.1007/s00198-012-1984-z. [PubMed: 22588182].
  • 11. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14(4):571-81. doi: 10.1016/j.jval.2010.11.010. [PubMed: 21669382].
  • 12. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003-8. doi: 10.1007/s00198-004-1652-z. [PubMed: 15167989].
  • 13. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25-39. doi: 10.18553/jmcp.2011.17.1.25. [PubMed: 21204588].
  • 14. Lin T, Yan SG, Cai XZ, Ying ZM, Yuan FZ, Zuo X. Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials. Int J Endocrinol. 2014;2014:796510. doi: 10.1155/2014/796510. [PubMed: 24511313]. [PubMed Central: PMC3912893].
  • 15. Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, et al. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health. 2013;13:15. doi: 10.1186/1472-6874-13-15. [PubMed: 23521803]. [PubMed Central: PMC3626542].
  • 16. Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, et al. Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161(10):711-23. doi: 10.7326/M14-0317. [PubMed: 25199883].
  • 17. Hawley S, Javaid MK, Rubin KH, Judge A, Arden NK, Vestergaard P, et al. Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. J Bone Miner Res. 2016;31(1):234-44. doi: 10.1002/jbmr.2595. [PubMed: 26174968].
  • 18. Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374(3):254-62. doi: 10.1056/NEJMcp1513724. [PubMed: 26789873].
  • 19. Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR, Solomon DH. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med. 2008;148(9):637-46. [PubMed: 18458276]. [PubMed Central: PMC3285566].
  • 20. Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011;22(3):943-54. doi: 10.1007/s00198-010-1309-z. [PubMed: 20532481]. [PubMed Central: PMC3277855].
  • 21. Cadarette SM, Levesque L, Mamdani M, Perreault S, Juurlink DN, Paterson JM, et al. Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. CMAJ Open. 2013;1(3):E97-E105. doi: 10.9778/cmajo.20130036. [PubMed: 25077113]. [PubMed Central: PMC3986012].
  • 22. Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int. 2009;20(6):973-8. doi: 10.1007/s00198-008-0772-2. [PubMed: 18946630]. [PubMed Central: PMC2711629].
  • 23. Ferrari S, Nakamura T, Hagino H, Fujiwara S, Lange JL, Watts NB. Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study. J Bone Miner Metab. 2011;29(5):561-70. doi: 10.1007/s00774-010-0249-1. [PubMed: 21225297].
  • 24. LeBlanc ES, Rosales AG, Balasubramanian A, O'Malley CD, Egbuna O, Friess D, et al. Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporos Int. 2015;26(2):713-25. doi: 10.1007/s00198-014-2941-9. [PubMed: 25354654].
  • 25. Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. Osteoporos Int. 2013;24(8):2345-52. doi: 10.1007/s00198-013-2332-7. [PubMed: 23612793].
  • 26. Diez-Perez A, Adachi JD, Adami S, Anderson FJ, Boonen S, Chapurlat R, et al. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res. 2014;29(1):260-7. doi: 10.1002/jbmr.2023. [PubMed: 23794198]. [PubMed Central: PMC4878143].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments